Amelia Szymanowska-Narloch¹, Dariusz Gawryluk², Katarzyna Błasińska-Przerwa³, Alicja Siemińska¹

¹Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland

²First Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

³Department of Radiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

Atypical manifestations of granulomatosis with polyangiitis: the diagnostic challenge for pulmonologists

Abstract

This is a review considering atypical manifestations of granulomatosis with polyangiitis (GPA). Virtually any organ can be affected, and in some patients, GPA can manifest unusually. Since thoracic involvement of GPA often predominates, the first who might be expected to establish a diagnosis are pulmonary specialists. We would like to familiarize pulmonary specialists with several extra-ELK (E: ear-nose-throat; L: lung; K: kidney) involvements of the disease. We describe sites rarely affected by GPA like the breast, skeletal system, orbit and eye, heart and vessels, central nervous system, urogenital system as well as endocrine and gastrointestinal tract involvement.

Key words: granulomatosis with polyangiitis, atypical manifestations, diagnosis, therapy, vasculitis

Adv Respir Med. 2019; 87: 244–253

Introduction

Granulomatosis with polyangiitis (GPA) is an uncommon necrotizing inflammation of small arteries and veins (*vasculitis*). It classically involves the vessels of the lungs, nasal passages, ear, throat and kidneys, and clinically manifests as a triad consisting of upper and lower airway disorders and glomerulonephritis. GPA can affect people at any age, although it is uncommon in children. Usually, GPA affects young or middle-aged adults. The cause of GPA remains unknown. However, the association of small vessel vasculitis with antineutrophil cytoplasmic antibodies, which are usually specific for proteinase 3, has yielded a new insight into pathogenic mechanisms [1]. Treatment depends on the extent of involvement and clinical course. In modern treatment strategies, intensive immunosuppressive therapy with a high dose of corticosteroids and cyclophosphamide or rituximab are used to induce remission [2, 3]. Once remission is achieved, patients are switched to less toxic maintenance immunosup-

pression, such as azathioprine and a low dose of corticosteroids. Normally, GPA responds quickly to immunosuppressive therapy, and prognosis, mainly limited by renal and pulmonary involvement, is rather good without higher mortality.

The wide range of clinical presentations is encompassed by ELK (E: ear-nose-throat; L: lung; K: kidney) classification, in which any combination or singular involvement of the major sites can be considered within the disease spectrum if supported by the appropriate pathologic or laboratory findings (the presence of a cytoplasmic antineutrophil cytoplasmic antibodies; cANCA). Other less frequently involved organ systems include the central and peripheral nervous system, skin, muscles, large joints, heart and eyes. Rarely, numerous other sites can be affected. Virtually any organ can be attacked, and in some patients, GPA can manifest unusually. Since thoracic involvement of GPA often predominates, the first who might be expected to establish a diagnosis are pulmonary specialists. Therefore, they should be aware of those less frequent mani-

Address for correspondence: Amelia Szymanowska-Narloch, Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland;

e-mail: aszymanowska@gumed.edu.pl

DOI: 10.5603/ARM.2019.0062

Received: 20.07.2019

Copyright © 2019 PTChP

ISSN 2451–4934

festations, seemingly not compatible with GPA or even mimicking other diseases, and keep in mind that limited forms of GPA with oligosymptomatic and atypical site involvement might occur. Thus, this awareness may be also useful when any new atypical manifestations occur in the course of disease with established diagnosis of GPA. Therefore, we would like to familiarize pulmonary specialists with several extra-ELK involvements of the disease.

Breast

Two reviews of the literature showed that breast involvement has been rarely reported in the literature [4, 5]. The most extensive review of the entity has been presented by Allende and Booth [4] and included 27 cases reported both in English and other languages. In turn, in their systematic review, Ren *et al.* [5] excluded reports published in non-English languages and not published in peer-review journals, and found 23 relevant cases. In Poland, two cases of breast involvement in GPA with lung and renal manifestations were described until now [6, 7]. The majority of cases regarded women between the third and seventh life decade and accompanied by systemic manifestations of the disease [4]. The GPA of the breast was usually unilateral and concomitant with lung and other organs involvement [8–13], although breast lesions can occur as the initial symptom of the disease [8, 12]. These lesions presented usually as nodules or masses, sometimes poorly circumscribed and of a firm consistency, with or without extensive necrosis (Figure 1). Such an appearance of the lesions resembled neoplastic disease of the breast [4, 14–15]. Occasionally, an association of a tumor-like lesion of the breast with multiple lung nodules strongly suggested a presumed diagnosis of metastatic carcinoma [12]. In any case, excluding breast carcinoma from the clinical differential diagnosis is required.

Skeletal system

Bones are involved in the course of GPA very rarely, except for facial bone involvement (mainly nasal septum destruction and sclerosing osteitis) associated with destructive inflammation of nasal passages and sinuses, or temporal bone (most often manifested as a mastoiditis). Clinical appearance of other bones involvement with GPA, concomitantly with lung involvement, has been described in single case reports. These include a case report presenting a 54-year-old man with

Figure 1. Well-with demarcated large ulceration central necrosis of right breast in the course of GPA

mass-like lung lesions accompanied by sternal osteomyelitis and destructive arthritis around the sternoclavicular joint [16]. Initial treatment with antibiotics and immunosuppressive therapy was non-effective and a new lung lesion occurred. A histopathological investigation of the lung mass showed chronic granulomatous inflammation with fibrinoid necrosis, findings accordant with GPA. In other case, granulomatosis with polyangiitis affected the skull base and manifested as a spontaneous skull base osteomyelitis with the development of cranial nerve palsies [17].

Another rare limited form of c-ANCA-positive GPA started with the bluish discoloration of the fingertips of both hands leading to spontaneous resorption of digits with acro-osteolysis [18]. The lesions were accompanied by general symptoms, including intermittent fever, myalgia and weight loss with an almost asymptomatic solitary cavitating nodule of the lung detected on high-resolution chest computed tomography. Sequentially, the patient displayed mononeuritis multiplex symptoms.

Although facial bone destruction as the most frequent bone manifestation of GPA mainly affects the nasal septum, contiguous granulomatous infiltration may spread to the soft tissues of the orbit and/or eye [19].

Orbito-ocular involvement

The orbit and eye are two of the most frequent body sites that could be affected by both granulomatous inflammation and focal ischemic vasculitis in the course of GPA. Ophthalmic involvement has been reported in up to 60% of patients diagnosed with GPA [20]. Orbital inflammation and necrotizing keratoscleritis,

Figure 2. Orbit MRI, T1-weighted coronal image showing contiguous infiltration which spreads from the ethmoid sinus to the left orbit. Some of the oculomotor muscles and optic nerve are infiltrated

episcleritis or conjunctivitis are the most characteristic presentations. Uveitis and granulomatous vasculitis of the retina and optic nerve are also relatively common ophthalmic manifestations of GPA. In turn, orbital mass is a rare presentation in GPA patients. In the study comprising 1,142 patients with GPA, only 5% developed orbital masses during a 5-year follow-up [21]. However, it is noteworthy that profound examination initiated by the presence of orbital mass may reveal asymptomatic pulmonary lesions [22]. Usually, orbito-ocular manifestations represent limited form of GPA but can be also the first presenting feature of GPA before progression to the lung and/or multisystem involvement [20, 23]. Thus, pulmonologists may encounter cases with pulmonary-renal involvement associated with initial orbito-ocular symptoms [24]. The presence of unexplained orbital inflammatory disease (Figures 2 and 3) in patient with pulmonary abnormalities in radiological imaging, should raise the question of possible GPA. A thorough clinical examination, laboratory testing and histological examination of lung biopsy specimens are essential to diagnose GPA and exclude potential mimics [25]. In turn, conjunctival ulceration as the presentation of GPA is rarely reported, and its occurrence in patient with remission of the disease may alert renewed systemic disease activity [26]. Few case reports have also claimed

Figure 3. Orbit MRI, T1-weighted axial image showing infiltration of the right orbit which includes oculomotor muscles

attention to rare orbito-ocular manifestation of GPA — acute unilateral dacryoadenitis, which may precede upper and lower respiratory tract involvement [27–29].

Ophthalmic lesions in the course of GPA can result not only from the involvement of soft tissues of the orbit but also from the involvement of the central nervous system, namely meningeal. For instance, because of morphological similarity and the anatomical continuity between the meningeal and the perioptic tissues, granulomatous inflammation may spread along such tissue planes and even lead to visual loss [24]. In other rare cases, optic neuritis in GPA without signs of orbital involvement is most likely caused by occlusive vasculitis of the vasa nervorum [30]. In every case, ocular lesions should be recognized as soon as possible so that an early diagnosis may allow appropriate treatment and good visual and general prognosis.

Nervous system involvement

The involvement of the nervous system by GPA, mainly as a peripheral or cranial mononeuritis multiplex, occurs relatively frequently, affecting 22–53% of patients [31–32]. Involvement limited only to the central nervous system (CNS) has been reported less frequently, in 2–8% of cases [32–33]. However, the use of new diagnostic

Figure 4. Brain MRI, FLAIR axial image showing chronic ischaemic stroke of the right hemisphere with retraction of the lateral ventricle. The thickening of meninges and frontal sinus inflammation are also seen

procedures, including modern neuroimaging, allowed detection of CNS involvement in up to 13% of GPA patients [34].

Three different types of nervous system involvement have been enumerated: 1) necrotizing vasculitis affecting the cerebral, spinal, and radicular vasculature; 2) direct granulomatous infiltration from contiguous lesions in the nose, paranasal sinuses and orbits; and 3) primary

necrotizing granulomas in the skull, meninges, brain or cranial nerves [35].

The first type is the most common, and both peripheral and cranial neuropathies are thought to be caused by the small vessels vasculitis [35]. Case reports on cranial neuropathies in GPA prove the true diagnostics difficulties, because sometimes the diagnosis is possible only when lung and/or renal extension of GPA follows its initial neurological manifestation [36–38]. Larger brain arteries are involved extremely rarely [39]. The unique case of GPA with paranasal sinuses, pulmonary and renal manifestations, and concomitant intracranial aneurysm of the anterior choroidal artery, complicated by rupture and subarachnoid hemorrhage, has been reported by Takei *et al.* [39]. Necrotizing vasculitis was also a pathogenic mechanism of ischemic infarction in few case reports [40–41].

Contiguous invasion of granuloma in CNS from extracranial sites of GPA, such as nose, paranasal sinuses and orbits has been incidentally described (Figures 4, 5A, 5B) [42]. Most often the pathogenic mechanism of lesions found in CNS is isolated cerebral or meningeal granulomatous inflammation.

Cerebral meningitis is one of the most frequent manifestations following cerebral ischemic or hemorrhagic lesions, observed in 42% of patients

Figure 5. Brain MRI. **A.** T1-weighted axial image with contrast enhancement. Images showing contiguous, contrast enhanced infiltration spreads from the posterior ethmoid sinus to the cavernous sinus, dura mater and the temporal lobe; **B.** FLAIR axial image. Local brain edema around inflammatory changes is also seen on FLAIR image

with GPA and CNS involvement [43]. That manifestation is considered to represent granulomatous infiltration of the dura mater of the brain and because the leptomeninges (pia and arachnoid) are affected incidentally, the terms pachymeningitis, hypertrophic pachymeningitis, or chronic hypertrophic pachymeningitis are commonly used referring to this condition. Moreover, whereas such neurological manifestations of GPA as mononeuritis multiplex, peripheral neuropathies, ischemic stroke, or intracerebral or subarachnoid hemorrhage are quickly put to diagnostic process, headache, a common symptom in meningeal involvement is often considered a symptom of chronic sinusitis or orbital disease. Pachymeningitis in the course of GPA may remain unrecognized for a long time [44], which in turn, can lead to delay in accurate diagnosis and timely treatment preventing serious local damage of the CNS. Pulmonologists should keep in mind that although pachymeningitis is associated with localized form of GPA, in single cases it was reported also in patients with lung involvement [45–48]. Therefore, in GPA patients with recent onset of severe headache, pachymeningitis should be considered and cranial MRI performed. This diagnostic procedure may reveal general thickening and pronounced enhancement of all meningeal structures.

Spinal dural and cord involvement presents as a spinal dural mass and in comparison to pachymeningitis, it is reported less frequently, and relapses are more often observed [43, 49]. It can be the initial GPA manifestation [50] or it can accompany other organs involvement, including the lungs, which pulmonary specialist should be aware of [49].

Cardiac involvement

Cardiac involvement in GPA is rare and usually associated with a threat of serious cardiac events and clinical courses refractory to immunosuppressive therapy. In the large multicenter North American study comprising 517 patients with GPA, cardiac involvement was shown in 3.3% [51]. Generally, all cardiac structures can be affected, but the most common cardiac manifestation in that study was pericarditis (35%) followed by cardiomyopathy (30%) and coronary artery disease (12%). Less frequent manifestations included valvular disease (6%) and severe conduction disorder (6%) [51]. However, the usage of magnetic resonance imaging in the study performed by the French Vasculitis Study Group revealed that specific cardiac involvement in GPA may be underestimated [52]. For instance,

pericarditis was detected in 26% of all studied GPA patients and late gadolinium enhancement, mostly nodular, in 32% of subjects. The reason for underdiagnosing cardiac manifestations of GPA is probably the fact that many of them can be subclinical or clinically asymptomatic [53–54]. Therefore, cardiac involvement in GPA was stated in only few case reports of congestive cardiomyopathy [55–57], myocarditis [58–61] and other cardiac conditions related to GPA [57, 62–65]. In case of coronary arteries involvement, it is noteworthy that clinically acute coronary syndrome in a patient with lung involvement can develop with no significant stenosis at catheterization [64]. Rhythm problems as a clinical cardiac manifestation of GPA with lung involvement are infrequent. The most often reported rhythm problems are supraventricular arrhythmias, followed by varying degree of heart block [57, 62–63]. Cardiac valvular involvement has been also rarely reported but it is a potentially fatal complication of GPA. In addition, this cardiac manifestation may misleadingly suggest infectious endocarditis [65]. To summarize, pulmonary specialists should remember that cardiac involvement in a GPA patient is heterogenous and can be usually clinically nonapparent, although potentially life-threatening [63]. They should also take into account that stenocardia symptoms or any other cardiac symptoms in a patient with suspected or confirmed GPA can indicate cardiac involvement. Profuse diagnostics, including magnetic resonance imaging, should be performed because confirmation of cardiac involvement dictates more aggressive treatment.

Systemic and regular cardiac assessment in the follow-up of patients with GPA is also recommended.

Large vessel vasculitis with or without aneurysm formation

Vasculitis of the large vessel with or without aneurysmatic changes is not typical finding in GPA. However, a review of the literature revealed a number of cases in which the involved arteries included the aorta [66–74], gastric [75], subclavian [76], pulmonary [74] and internal carotid artery [39]. In most instances, depending on the artery affected, abdominal pain was the presenting symptom [66, 68, 70–71]. In other cases, back pain [69, 72], arm pain [76], headache due to subarachnoid hemorrhage [39] and atrioventricular block were the presenting symptoms. In most of the cases, involvement of large vessels was

Figure 6. Axial chest CT scan. Large saccular aneurysm of aortic arch and descending aorta adjacent to pulmonary cavity lesion

Figure 7. Abdominal CT scan. Retroperitoneal inflammatory infiltration involving iliac vessels and left ureter causing hydronephrosis in 48 years old man with GPA

shown simultaneously at the time of diagnosis of GPA with pulmonary involvement (Figure 6) [39, 68–69, 71–74, 76], but clinical presentation of large vessels can manifest several months before [66] or after the diagnosis [70].

It seems justifiable to consider GPA in differential diagnosis of unexplained abdominal pain when aortic aneurysm is found [68, 71]. Especially, when a young patient presents with abdominal aortic aneurysm, GPA may be an underlying cause [71]. The early diagnosis is of great importance, because surgical treatment (vascular intervention) and immunosuppressive agents prevent a development of further aneurysm, which is a life-threatening complication.

Urogenital manifestations of GPA

Urogenital manifestations of GPA are found relatively rarely — in less than 1% of patients [77–80]. They can be present at the onset of the disease, together with lower respiratory system manifestations, sometimes as its first clinical evidence (Figure 7). In other cases, they appear before subsequent development of pulmonary involvement of GPA or as a symptom of GPA relapse [79, 81]. Symptomatic urogenital manifestations in case reports with concomitant lung involvement included prostatitis [79, 82], epididymitis [79, 81], renal mass [79], ureteral stenosis [82], and penile ulceration [83–84]. Some presentations, such as a renal or prostate mass, mimic cancer or

an abscess. Considering GPA in the differential diagnosis might help avoiding unnecessary radical surgery, especially that urogenital symptoms can be promptly resolved with corticosteroids and/or immunosuppressive agents.

Endocrine involvement

Endocrine involvement, particularly of the thyroid gland, adrenal gland and hypopituitary is extremely rare. The single case reports describing cold thyroid nodules or suprarenal mass of GPA origin and concomitant pulmonary GPA involvements have been published to date [85–87]. Regarding pituitary involvement in GPA, recent search for the cases indicated in the literature revealed 58 published reports. This rare complication more frequently affected females (69%) than males [88]. Moreover, pituitary involvement has predominantly concerned posterior gland and is usually associated with other organ involvement [88, 89]. Numerous patients (43–73%) with pituitary manifestation of GPA have concomitant lung lesions [88, 89]. Cranial diabetes insipidus was the most common endocrine abnormality found in 81% of cases [88]. Anterior pituitary hormone abnormalities, including hypogonadism, secondary hypothyroidism, hyperprolactinemia and growth hormone deficiency, are less frequent. Pulmonologists ought to keep in mind the possibility of pituitary involvement. In every patient with pulmonary presentation of GPA who displays unusual

symptoms such as polydipsia and polyuria, this rare involvement should be considered [90, 91].

Gastrointestinal tract involvement

GPA as a predominantly renopulmonary disorder rarely has gastrointestinal system manifestations and the involvement of this system usually occurs long after the onset of initial symptoms [92]. Among them, the pancreas, liver or colon involvement is exceedingly rarely reported [92–95]. For instance, only single case reports described overt clinical manifestation of pancreatic GPA, including painless jaundice or recurrent acute pancreatitis as an initial presentation of GPA or presentation concomitant with the typical pulmonary and/or renal involvement [93–94]. Moreover, when a patient with established GPA develops otherwise unexplained acute pancreatitis, reactivation of the disease should be considered by pulmonologists [93]. Thus, involvement of the pancreas, although uncommon, should be taken into account in the differential diagnosis in cases of abdominal pain with hyperamylasemia or cases clinically mimicking pancreatic carcinoma.

Similarly, liver involvement in GPA is very rare with only few case reports in the literature, presenting patients with concomitant systemic disease affecting the lungs [95]. Though very infrequent, this organ involvement is potentially fatal due to a risk of liver failure. Therefore, it should not be forgotten as a manifestation of GPA.

There are also few case reports of gastric and intestinal involvement where severe colitis with gastrointestinal hemorrhage was a presenting feature of GPA preceding further progression of the disease with pulmonary and other organs manifestations [92, 96–97]. Other single cases reported colitis following initial pulmonary and/or other organs manifestations of GPA [98–102].

Conclusions

The presented atypical organ involvement of GPA does not exhaust the topic of all possible manifestations of the disease. Any nonspecific illness concomitant with pulmonary lesions in GPA patients should raise the suspicion of unusual involvement of the disease, and differential diagnostics is required to confirm or exclude this suspicion. Understanding of a broad spectrum of possible organ involvement in GPA, sometimes potentially fatal, may help in timely diagnosis and treatment.

Therefore, collecting data in registry for GPA patients (e.g. POLVAS in Poland) and co-operation among registries, will broaden our knowledge about the disease and have impact on directions in future research. Proper diagnostics of patients with atypical GPA manifestations is very important, as it allows the implementation of appropriate treatment according to the current guidelines of the American College of Rheumatology (ACR), as well as British Society of Rheumatology and British Health Professionals in Rheumatology (BSR and BHPR).

Conflict of interest

None declared.

References:

1. Yi ES, Colby TV. Wegener's granulomatosis. *Semin Diagn Pathol.* 2001; 18(1): 34–46, indexed in Pubmed: [11296992](#).
2. Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. *Rheumatology (Oxford).* 2014; 53(12): 2306–2309, doi: [10.1093/rheumatology/ket445](#), indexed in Pubmed: [24729399](#).
3. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Ann Rheum Dis.* 2016; 75(9): 1583–1594, doi: [10.1136/annrheumdis-2016-209133](#), indexed in Pubmed: [27338776](#).
4. Allende DS, Booth CN. Wegener's granulomatosis of the breast: a rare entity with daily clinical relevance. *Ann Diagn Pathol.* 2009; 13(5): 351–357, doi: [10.1016/j.anndiagpath.2009.04.005](#), indexed in Pubmed: [19751914](#).
5. Ren J, Liu J, Su J, et al. Systemic vasculitis involving the breast: a case report and literature review. *Rheumatol Int.* 2019; 39(8): 1447–1455, doi: [10.1007/s00296-019-04279-8](#), indexed in Pubmed: [30874872](#).
6. Barczyńska T, Dankiewicz-Fares I, Bilińska-Reszkowska H, et al. Atypical location of Wegener's granulomatosis with breast involvement: case report. *Ann Acad Med Stetin.* 2011; 57(3): 70–76, indexed in Pubmed: [23383550](#).
7. Ryba M, Konieczny A, Hruby Z. Breast involvement in anti-neutrophil cytoplasmic antibodies positive granulomatosis with polyangiitis in a 64-year-old female patient. *Arch Rheumatol.* 2017; 32(4): 358–360, doi: [10.5606/ArchRheumatol.2017.6321](#), indexed in Pubmed: [29901008](#).
8. Jordan JM, Rowe WT, Allen NB. Wegener's granulomatosis involving the breast. Report of three cases and review of the literature. *Am J Med.* 1987; 83(1): 159–164, doi: [10.1016/0002-9343\(87\)90513-4](#), indexed in Pubmed: [3300322](#).
9. Neralić-Meniga I, Ivanovi-Herceg Z, Mazuranić I, et al. Wegener's granulomatosis of the breast. *Wien Klin Wochenschr.* 2006; 118(3-4): 120–123, doi: [10.1007/s00508-006-0536-y](#), indexed in Pubmed: [16703257](#).
10. Veerysami M, Freeth M, Carmichael AR, et al. Wegener's granulomatosis of the breast. *Breast J.* 2006; 12(3): 268–270, doi: [10.1111/j.1075-122X.2006.00254.x](#), indexed in Pubmed: [16684328](#).
11. Comas AGV, Diana CA, Crespo CC, et al. Wegener's granulomatosis presented as recurrent breast abscess. *Breast J.* 2010; 16(1): 82–84, doi: [10.1111/j.1524-4741.2009.00851.x](#), indexed in Pubmed: [19968659](#).
12. Daguzan M, Martinez-Mena C, Hermans P. A case of breast necrosis. *Rev Med Brux.* 2012; 33(2): 112–115, indexed in Pubmed: [22812057](#).
13. Lluch J, Montserrat Pérez-Tapia L, Taco-Sánchez MD, et al. Breast involvement in granulomatosis with polyangiitis. *Joint Bone Spine.* 2019; 86(2): 263–264, doi: [10.1016/j.jbspin.2018.05.004](#), indexed in Pubmed: [29800711](#).

14. Georgescu R, Podeanu MD, Colcer I, et al. Wegener's granulomatosis of the breast with peculiar radiological aspect mimicking breast carcinoma. *Breast J.* 2015; 21(5): 550–552, doi: [10.1111/tbj.12458](#), indexed in Pubmed: [26190690](#).
15. Mengoli MC, Ragazzi M, Lococo F, et al. Breast granulomatosis with polyangiitis mimicking breast cancer. *Pathologica.* 2017; 109(4): 405–407, indexed in Pubmed: [29449734](#).
16. Kim SD, Kim GW, Kim TE, et al. Granulomatosis with polyangiitis (Wegener granulomatosis) as a differential diagnosis of sternal osteomyelitis: the challenges in diagnosis. *J Clin Rheumatol.* 2013; 19(8): 446–448, doi: [10.1097/RHU.0000000000000036](#), indexed in Pubmed: [24263148](#).
17. Harrison L, McNally J, Corbridge R. Granulomatosis with polyangiitis affecting the skull base and manifesting as spontaneous skull base osteomyelitis. *BMJ Case Rep.* 2016; 2016, doi: [10.1136/bcr-2015-213912](#), indexed in Pubmed: [26929226](#).
18. Modi M, Vats AK, Prabhakar S, et al. Acro-osteolysis and mononeuritis multiplex as a presenting symptom of systemic angitis of Wegener's type. *Indian J Med Sci.* 2007; 61(4): 212–215, doi: [10.4103/0019-5359.31155](#), indexed in Pubmed: [17401258](#).
19. Muller K, Lin JH. Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings. *Arch Pathol Lab Med.* 2014; 138(8): 1110–1114, doi: [10.5858/arpa.2013-0006-RS](#), indexed in Pubmed: [25076302](#).
20. Pakrou N, Selva D, Leibovitch I. Wegener's granulomatosis: ophthalmic manifestations and management. *Semin Arthritis Rheum.* 2006; 35(5): 284–292, doi: [10.1016/j.semarthrit.2005.12.003](#), indexed in Pubmed: [16616151](#).
21. Holle JU, Voigt C, Both M, et al. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. *Rheumatology (Oxford).* 2013; 52(5): 875–882, doi: [10.1093/rheumatology/kes382](#), indexed in Pubmed: [23293138](#).
22. Lu CW, Liu XF, Luan Y, et al. A case report of the orbit, ocular association and the lung in granulomatosis with polyangiitis: A diagnostic challenge. *Exp Ther Med.* 2017; 13(6): 3337–3340, doi: [10.3892/etm.2017.4408](#), indexed in Pubmed: [28587410](#).
23. Ahmed M, Niffenegger JH, Jakobiec FA, et al. Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation. *Int Ophthalmol.* 2008; 28(1): 35–46, doi: [10.1007/s10792-007-9109-y](#), indexed in Pubmed: [17589807](#).
24. Takazawa T, Ikeda K, Nagaoka T, et al. Wegener granulomatosis-associated optic perineuritis. *Orbit.* 2014; 33(1): 13–16, doi: [10.3109/01676830.2013.841716](#), indexed in Pubmed: [24144064](#).
25. Danda D, Mathew AJ, Mathew J. Wegener's granulomatosis: a rare presentation. *Clin Rheumatol.* 2008; 27(2): 273–275, doi: [10.1007/s10067-007-0719-6](#), indexed in Pubmed: [18004612](#).
26. Fortney AC, Chodosh J. Conjunctival ulceration in recurrent Wegener granulomatosis. *Cornea.* 2002; 21(6): 623–624, doi: [10.1097/00003226-200208000-00022](#), indexed in Pubmed: [12131047](#).
27. Soheilian M, Bagheri A, Aletaha M. Dacryoadenitis as the earliest presenting manifestation of systemic Wegener's granulomatosis. *Eur J Ophthalmol.* 2002; 12(3): 241–243, doi: [10.1177/112067210201200313](#), indexed in Pubmed: [12113573](#).
28. Kiratli H, Sekeroğlu MA, Soylemezoğlu F. Unilateral dacryoadenitis as the sole presenting sign of Wegener's granulomatosis. *Orbit.* 2008; 27(3): 157–160, doi: [10.1080/01676830701523863](#), indexed in Pubmed: [18569819](#).
29. Hibino M, Kondo T. Dacryoadenitis with Ptosis and Diplopia as the Initial Presentation of Granulomatosis with Polyangiitis. *Intern Med.* 2017; 56(19): 2649–2653, doi: [10.2169/internal-medicine.8761-16](#), indexed in Pubmed: [28883246](#).
30. Huchzermeyer C, Mardin C, Holbach L, et al. Successful remission induction with a combination therapy of rituximab, cyclophosphamide, and steroids in a patient with refractory optic neuritis in Wegener's granulomatosis. *Clin Rheumatol.* 2013; 32 Suppl 1: S97–101, doi: [10.1007/s10067-010-1561-9](#), indexed in Pubmed: [20862503](#).
31. Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. *Ann Intern Med.* 1983; 98(1): 76–85, doi: [10.7326/0003-4819-98-1-76](#), indexed in Pubmed: [6336643](#).
32. Nishino H, Rubino FA, DeRemee RA, et al. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. *Ann Neurol.* 1993; 33(1): 4–9, doi: [10.1002/ana.410330103](#), indexed in Pubmed: [8388187](#).
33. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med.* 1992; 116(6): 488–498, doi: [10.7326/0003-4819-116-6-488](#), indexed in Pubmed: [1739240](#).
34. Fragoulis GE, Lionaki S, Venetsanopoulou A, et al. Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study. *Clin Rheumatol.* 2018; 37(3): 737–747, doi: [10.1007/s10067-017-3835-y](#), indexed in Pubmed: [28914375](#).
35. Drachman DA. Neurological complications of Wegener's granulomatosis. *Arch Neurol.* 1963; 8(2): 145–155, doi: [10.1001/archneur.1963.00460020045003](#).
36. Nikolau AC, Vlachtsis KC, Daniilidis MA, et al. Wegener's granulomatosis presenting with bilateral facial nerve palsy. *Eur Arch Otorhinolaryngol.* 2001; 258(4): 198–202, doi: [10.1007/s004050100327](#), indexed in Pubmed: [11407453](#).
37. Armani M, Spinazzi M, Andriago C, et al. Severe dysphagia in lower cranial nerve involvement as the initial symptom of Wegener's granulomatosis. *J Neurol Sci.* 2007; 263(1–2): 187–190, doi: [10.1016/j.jns.2007.05.029](#), indexed in Pubmed: [17658554](#).
38. Lee E, Park J, Choi SH, et al. Seronegative granulomatosis with polyangiitis presenting with multiple cranial nerve palsies. *Neuropathology.* 2018; 38(2): 192–197, doi: [10.1111/neup.12437](#), indexed in Pubmed: [29139157](#).
39. Takei H, Komaba Y, Kitamura H, et al. Aneurysmal subarachnoid hemorrhage in a patient with Wegener's granulomatosis. *Clin Exp Nephrol.* 2004; 8(3): 274–278, doi: [10.1007/s10157-004-0280-4](#), indexed in Pubmed: [15480908](#).
40. Sivakumar MR, Chandrakantan A. A rare case of stroke in Wegener's granulomatosis. *Cerebrovasc Dis.* 2002; 13(2): 143–144, doi: [10.1159/000047765](#), indexed in Pubmed: [11867890](#).
41. Peng W, Wang X. Hypertrophic pachymeningitis and cerebral infarction resulting from ANCA-associated vasculitis. *Neurol India.* 2012; 60(4): 424–426, doi: [10.4103/0028-3886.100711](#), indexed in Pubmed: [22954981](#).
42. Mujagic S, Sarihodzic S, Huseinagic H, et al. Wegener's granulomatosis of the paranasal sinuses with orbital and central nervous system involvement—diagnostic imaging. *Acta Neurol Belg.* 2011; 111(3): 241–244, indexed in Pubmed: [22141293](#).
43. De Luna G, Terrier B, Kaminsky P, et al. Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. *Rheumatology (Oxford).* 2015; 54(3): 424–432, doi: [10.1093/rheumatology/keu336](#), indexed in Pubmed: [25187644](#).
44. Sakellariou GT, Kefala N. Pachymeningitis in granulomatosis with polyangiitis: a case report and a review of the literature. *Case Rep Rheumatol.* 2013; 2013: 840984, doi: [10.1155/2013/840984](#), indexed in Pubmed: [23984161](#).
45. Di Comite G, Bozzolo EP, Praderio L, et al. Meningeal involvement in Wegener's granulomatosis is associated with localized disease. *Clin Exp Rheumatol.* 2006; 24(2 Suppl 41): S60–S64, indexed in Pubmed: [16859598](#).
46. Hayakawa M, Nishijima M, Inui K, et al. A case of Wegener's granulomatosis with pachymeningitis. *Nihon Kokyuki Gakkai Zasshi.* 2009; 47(4): 314–319, indexed in Pubmed: [19455962](#).
47. Sharma A, Kumar S, Wanchu A, et al. Successful treatment of hypertrophic pachymeningitis in refractory Wegener's granulomatosis with rituximab. *Clin Rheumatol.* 2010; 29(1): 107–110, doi: [10.1007/s10067-009-1291-z](#), indexed in Pubmed: [19802640](#).
48. Choi HAh, Lee Miji, Chung CS. Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis. *J Neurol.* 2017; 264(4): 724–732, doi: [10.1007/s00415-017-8416-0](#), indexed in Pubmed: [28220286](#).
49. Albayram S, Kizilkilic O, Adaletli I, et al. MR imaging findings of spinal dural involvement with Wegener granulomatosis. *AJNR Am J Neuroradiol.* 2002; 23(9): 1603–1606, indexed in Pubmed: [12372756](#).
50. Kelly PJ, Toker DE, Boyer P, et al. Granulomatous compressive thoracic myelopathy as the initial manifestation of Wegener's granulomatosis. *Neurology.* 1998; 51(6): 1769–1770, doi: [10.1212/wnl.51.6.1769](#), indexed in Pubmed: [9855551](#).

51. McGeoch L, Carette S, Cuthbertson D, et al. Vasculitis Clinical Research Consortium. Cardiac involvement in granulomatosis with polyangiitis. *J Rheumatol*. 2015; 42(7): 1209–1212, doi: [10.3899/jrheum.141513](#), indexed in Pubmed: [25934819](#).
52. Pugnet G, Gouya H, Puéchal X, et al. French Vasculitis Study Group. Cardiac involvement in granulomatosis with polyangiitis: a magnetic resonance imaging study of 31 consecutive patients. *Rheumatology (Oxford)*. 2017; 56(6): 947–956, doi: [10.1093/rheumatology/kew490](#), indexed in Pubmed: [28339663](#).
53. Morelli S, Gurgu Di Castelmenardo AM, Conti F, et al. Cardiac involvement in patients with Wegener's granulomatosis. *Rheumatol Int*. 2000; 19(6): 209–212, doi: [10.1007/s002960000059](#), indexed in Pubmed: [11063289](#).
54. Oliveira GHM, Seward JB, Tsang TSM, et al. Echocardiographic findings in patients with Wegener granulomatosis. *Mayo Clin Proc*. 2005; 80(11): 1435–1440, doi: [10.4065/80.11.1435](#), indexed in Pubmed: [16295023](#).
55. Day JD, Ellison KE, Schnittger I, et al. Wegener's granulomatosis presenting as dilated cardiomyopathy. *West J Med*. 1996; 165(1-2): 64–66, indexed in Pubmed: [8855696](#).
56. Delevaux I, Hoën B, Seltun-Suty C, et al. Relapsing congestive cardiomyopathy in Wegener's granulomatosis. *Mayo Clin Proc*. 1997; 72(9): 848–850, doi: [10.4065/72.9.848](#), indexed in Pubmed: [9294532](#).
57. Sarlon G, Durant C, Grandgeorge Y, et al. Cardiac involvement in Wegener's granulomatosis: report of four cases and review of the literature. *Rev Med Interne*. 2010; 31(2): 135–139, doi: [10.1016/j.revmed.2009.06.007](#), indexed in Pubmed: [19783329](#).
58. To A, De Zoysa J, Christiansen JP, et al. Cardiomyopathy associated with Wegener's granulomatosis. *Heart*. 2007; 93(8): 984, doi: [10.1136/hrt.2006.098038](#), indexed in Pubmed: [17639115](#).
59. Brihaye B, Aouba A, Pagnoux C, et al. Rituximab reversed cardiac involvement of Wegener's granulomatosis: magnetic resonance imaging assessment. *Presse Med*. 2008; 37(3 Pt 1): 412–415, doi: [10.1016/j.lpm.2007.08.019](#), indexed in Pubmed: [18276102](#).
60. Florian A, Slavich M, Blockmans D, et al. Cardiac involvement in granulomatosis with polyangiitis (Wegener granulomatosis). *Circulation*. 2011; 124(13): e342–e344, doi: [10.1161/CIRCULATIONAHA.111.030809](#), indexed in Pubmed: [21947937](#).
61. Munch A, Sundbøll J, Høyer S, et al. Acute myocarditis in a patient with newly diagnosed granulomatosis with polyangiitis. *Case Rep Cardiol*. 2015; 2015: 134529, doi: [10.1155/2015/134529](#), indexed in Pubmed: [26770838](#).
62. Elikowski W, Baszko A, Puszczewicz M, et al. Complete heart block due to Wegener's granulomatosis: a case report and literature review. *Kardiol Pol*. 2006; 64(6): 622–627, indexed in Pubmed: [16810583](#).
63. Lin CH, Tsai SH, Chen HC, et al. Heart blockage in a patient with cavitary lung lesions. *Am J Emerg Med*. 2012; 30(8): 1663.e1–1663.e3, doi: [10.1016/j.ajem.2011.09.011](#), indexed in Pubmed: [22100479](#).
64. Asdonk T, Tiyerili V, Dörner J, et al. Acute coronary syndrome as a cardiac manifestation of granulomatosis with polyangiitis. *Dtsch Med Wochenschr*. 2013; 138(5): 213–217, doi: [10.1055/s-0032-1327419](#), indexed in Pubmed: [23340944](#).
65. Espitia O, Droy L, Pattier S, et al. A case of aortic and mitral valve involvement in granulomatosis with polyangiitis. *Cardiovasc Pathol*. 2014; 23(6): 363–365, doi: [10.1016/j.carpath.2014.07.007](#), indexed in Pubmed: [25194969](#).
66. Sieber SC, Cuello B, Gelfman NA, et al. Pulmonary capillaritis and glomerulonephritis in an antineutrophil cytoplasmic antibody-positive patient with prior granulomatous aortitis. *Arch Pathol Lab Med*. 1990; 114(12): 1223–1226, indexed in Pubmed: [2252417](#).
67. den Bakker MA, Tangkau PL, Steffens TW, et al. Rupture of a hepatic artery aneurysm caused by Wegener's granulomatosis. *Pathol Res Pract*. 1997; 193(1): 61–66, doi: [10.1016/S0344-0338\(97\)80096-9](#), indexed in Pubmed: [9112274](#).
68. Blockmans D, Baeyens H, Van Loon R, et al. Periaortitis and aortic dissection due to Wegener's granulomatosis. *Clin Rheumatol*. 2000; 19(2): 161–164, doi: [10.1007/s100670050038](#), indexed in Pubmed: [10791632](#).
69. Carels T, Verbeken E, Blockmans D. p-ANCA-associated periaortitis with histological proof of Wegener's granulomatosis: case report. *Clin Rheumatol*. 2005; 24(1): 83–86, doi: [10.1007/s10067-004-0998-0](#), indexed in Pubmed: [15565392](#).
70. Levin A, Kasem S, Mader R, et al. Wegener granulomatosis with back pain, periaortitis, and dural inflammation developing while receiving monthly cyclophosphamide. *J Clin Rheumatol*. 2006; 12(6): 294–297, doi: [10.1097/01.rhu.0000249863.76020.dd](#), indexed in Pubmed: [17149061](#).
71. Durai R, Agrawal R, Piper K, et al. Wegener's granulomatosis presenting as an abdominal aortic aneurysm: a case report. *Cases J*. 2009; 2: 9346, doi: [10.1186/1757-1626-2-9346](#), indexed in Pubmed: [20066062](#).
72. Kasagi S, Saegusa J, Tsuji G, et al. Epidural spinal tumor and periaortitis as rare complications of Wegener's granulomatosis. *Mod Rheumatol*. 2011; 21(6): 678–683, doi: [10.1007/s10165-011-0456-1](#), indexed in Pubmed: [21691846](#).
73. Kim JB, Kim W, Park MJ. Reversal of aortic root inflammation after treatment of Wegener's granulomatosis. *Heart*. 2013; 99(7): 507, doi: [10.1136/heartjnl-2012-302307](#), indexed in Pubmed: [23150194](#).
74. Ozaki T, Maeshima K, Kiyonaga Y, et al. Large-vessel involvement in granulomatosis with polyangiitis successfully treated with rituximab: A case report and literature review. *Mod Rheumatol*. 2017; 27(4): 699–704, doi: [10.3109/14397595.2015.1021950](#), indexed in Pubmed: [25736357](#).
75. Aoki N, Soma K, Owada T, et al. Wegener's granulomatosis complicated by arterial aneurysm. *Intern Med*. 1995; 34(8): 790–793, doi: [10.2169/internalmedicine.34.790](#), indexed in Pubmed: [8563123](#).
76. Shitrit D, Shitrit ABG, Starobin D, et al. Large vessel aneurysms in Wegener's granulomatosis. *J Vasc Surg*. 2002; 36(4): 856–858, doi: [10.1067/mva.2002.126088](#), indexed in Pubmed: [12368751](#).
77. Anderson G, Coles ET, Crane M, et al. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. *Q J Med*. 1992; 83(302): 427–438, indexed in Pubmed: [1448544](#).
78. Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. *Arthritis Rheum*. 2011; 63(1): 257–266, doi: [10.1002/art.27763](#), indexed in Pubmed: [20862686](#).
79. Dufour JF, Le Gallou T, Cordier JF, et al. French Center-East Internists Group, French Vasculitis Study Group. Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature. *Medicine (Baltimore)*. 2012; 91(2): 67–74, doi: [10.1097/MD.0b013e318239add6](#), indexed in Pubmed: [22391468](#).
80. Thai LH, Charles P, Resche-Rigon M, et al. Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients. *Autoimmun Rev*. 2014; 13(3): 313–318, doi: [10.1016/j.autrev.2013.11.003](#), indexed in Pubmed: [24225075](#).
81. Miller DC, Koss MN. Wegener granulomatosis presenting as epididymitis. *Urology*. 2009; 73(6): 1225–1226, doi: [10.1016/j.urology.2009.02.015](#), indexed in Pubmed: [19376569](#).
82. Middleton G, Karp D, Lee E, et al. Wegener's granulomatosis presenting as lower back pain with prostatitis and ureteral obstruction. *J Rheumatol*. 1994; 21(3): 566–569, indexed in Pubmed: [8006905](#).
83. Matsuda S, Mitsukawa S, Ishii N, et al. A case of Wegener's granulomatosis with necrosis of the penis. *Tohoku J Exp Med*. 1976; 118(2): 145–151, doi: [10.1620/tjem.118.145](#), indexed in Pubmed: [982429](#).
84. Ebo DG, Mertens AV, De Clerck LS, et al. Relapse of Wegener's granulomatosis presenting as a destructive urethritis and penile ulceration. *Clin Rheumatol*. 1998; 17(3): 239–241, doi: [10.1007/bf01451056](#), indexed in Pubmed: [9694061](#).
85. Zagdańska J, Krakówka P, Walecki J. Wegener's granulomatosis with adrenal gland involvement. *Pneumonol Pol*. 1989; 57(2): 134–139, indexed in Pubmed: [2587400](#).
86. Schmitz KJ, Baumgaertel MW, Schmidt C, et al. Wegener's granulomatosis in the thyroid mimicking a tumour. *Virchows Arch*. 2008; 452(5): 571–574, doi: [10.1007/s00428-007-0573-6](#), indexed in Pubmed: [18305956](#).
87. Khalifa M, BenFredj H, Ghannouchi N, et al. Thyroid involvement in Wegener's granulomatosis: a case report. *Rev Med Interne*. 2009; 30(2): 176–178, doi: [10.1016/j.revmed.2008.04.015](#), indexed in Pubmed: [18849094](#).

88. Peters JE, Gupta V, Saeed IT, et al. Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review. *BMC Neurol.* 2018; 18(1): 59, doi: [10.1186/s12883-018-1058-8](https://doi.org/10.1186/s12883-018-1058-8), indexed in Pubmed: [29716529](https://pubmed.ncbi.nlm.nih.gov/29716529/).
89. Yong TY, Li JYZ, Amato L, et al. Pituitary involvement in Wegener's granulomatosis. *Pituitary.* 2008; 11(1): 77–84, doi: [10.1007/s11102-007-0021-2](https://doi.org/10.1007/s11102-007-0021-2), indexed in Pubmed: [17492510](https://pubmed.ncbi.nlm.nih.gov/17492510/).
90. Hurst NP, Dunn NA, Chalmers TM. Wegener's granulomatosis complicated by diabetes insipidus. *Ann Rheum Dis.* 1983; 42(5): 600–601, doi: [10.1136/ard.42.5.600](https://doi.org/10.1136/ard.42.5.600), indexed in Pubmed: [6625709](https://pubmed.ncbi.nlm.nih.gov/6625709/).
91. Düzgün N, Morris Y, Güllü S, et al. Diabetes insipidus presentation before renal and pulmonary features in a patient with Wegener's granulomatosis. *Rheumatol Int.* 2005; 26(1): 80–82, doi: [10.1007/s00296-005-0583-0](https://doi.org/10.1007/s00296-005-0583-0), indexed in Pubmed: [15864593](https://pubmed.ncbi.nlm.nih.gov/15864593/).
92. Steele C, Bohra S, Broe P, et al. Acute upper gastrointestinal haemorrhage and colitis: an unusual presentation of Wegener's granulomatosis. *Eur J Gastroenterol Hepatol.* 2001; 13(8): 993–995, doi: [10.1097/00042737-200108000-00023](https://doi.org/10.1097/00042737-200108000-00023), indexed in Pubmed: [11507371](https://pubmed.ncbi.nlm.nih.gov/11507371/).
93. Kemp JA, Arora S, Fawaz K. Recurrent acute pancreatitis as a manifestation of Wegener's granulomatosis. *Dig Dis Sci.* 1990; 35(7): 912–915, doi: [10.1007/bf01536809](https://doi.org/10.1007/bf01536809), indexed in Pubmed: [2364848](https://pubmed.ncbi.nlm.nih.gov/2364848/).
94. O'Neil KM, Jones DM, Lawson JM. Wegener's granulomatosis masquerading as pancreatic carcinoma. *Dig Dis Sci.* 1992; 37(5): 702–704, doi: [10.1007/bf01296425](https://doi.org/10.1007/bf01296425), indexed in Pubmed: [1563310](https://pubmed.ncbi.nlm.nih.gov/1563310/).
95. Holl-Ulrich K, Klass M. Wegener's granulomatosis with granulomatous liver involvement. *Clin Exp Rheumatol.* 2010; 28(1 Suppl 57): 88–89, indexed in Pubmed: [20412710](https://pubmed.ncbi.nlm.nih.gov/20412710/).
96. Qian Qi, Cornell L, Chandan V, et al. Hemorrhagic colitis as a presenting feature of Wegener granulomatosis. *J Gastrointest Liver Dis.* 2010; 19(4): 445–447, indexed in Pubmed: [21188339](https://pubmed.ncbi.nlm.nih.gov/21188339/).
97. Sinnott JD, Matthews P, Fletcher S. Colitis: an unusual presentation of Wegener's granulomatosis. *BMJ Case Rep.* 2013; 2013, doi: [10.1136/bcr-2012-007566](https://doi.org/10.1136/bcr-2012-007566), indexed in Pubmed: [23436885](https://pubmed.ncbi.nlm.nih.gov/23436885/).
98. Tupler RH, McCuskey WH. Wegener granulomatosis of the colon: CT and histologic correlation. *J Comput Assist Tomogr.* 1991; 15(2): 314–316, doi: [10.1097/00004728-199103000-00025](https://doi.org/10.1097/00004728-199103000-00025), indexed in Pubmed: [2002115](https://pubmed.ncbi.nlm.nih.gov/2002115/).
99. Storesund B, Gran JT, Koldingsnes W. Severe intestinal involvement in Wegener's granulomatosis: report of two cases and review of the literature. *Br J Rheumatol.* 1998; 37(4): 387–390, doi: [10.1093/rheumatology/37.4.387](https://doi.org/10.1093/rheumatology/37.4.387), indexed in Pubmed: [9619888](https://pubmed.ncbi.nlm.nih.gov/9619888/).
100. Pickhardt PJ, Curran VW. Fulminant enterocolitis in Wegener's granulomatosis: CT findings with pathologic correlation. *AJR Am J Roentgenol.* 2001; 177(6): 1335–1337, doi: [10.2214/ajr.177.6.1771335](https://doi.org/10.2214/ajr.177.6.1771335), indexed in Pubmed: [11717078](https://pubmed.ncbi.nlm.nih.gov/11717078/).
101. Akça T, Çolak T, Çağlıkölekçi M, et al. Intestinal perforation in Wegener's granulomatosis: a case report. *Ulus Travma Acil Cerrahi Derg.* 2005; 11(4): 348–351, indexed in Pubmed: [16341975](https://pubmed.ncbi.nlm.nih.gov/16341975/).
102. Deniz K, Özşeker HS, Balas S, et al. Intestinal involvement in Wegener's granulomatosis. *J Gastrointest Liver Dis.* 2007; 16(3): 329–331, indexed in Pubmed: [17925931](https://pubmed.ncbi.nlm.nih.gov/17925931/).